Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2)

Abstract Background Heterozygous familial hypercholesterolemia (HeFH) is largely underdiagnosed and undertreated in China where few patients achieved recommended target levels of low density lipoprotein cholesterol (LDL-C). We conducted the first randomized, placebo-controlled clinical trial in Chin...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Meng Chai, Yongming He, Wang Zhao, Xuebin Han, Guoyan Zhao, Xueping Ma, Ping Qiao, Dongmei Shi, Yuyang Liu, Wei Han, Pei An, Haoyu Li, Shuling Yan, Qingyang Ma, Huan Deng, Lei Qian, Yujie Zhou, on behalf of CREDIT-2 investigators
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	BMC 2023-02-01
Serie:	BMC Medicine
Soggetti:	Tafolecimab PCSK9 LDL-C HeFH
Accesso online:	https://doi.org/10.1186/s12916-023-02797-8
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!